vs
Byrna Technologies Inc.（BYRN）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Byrna Technologies Inc.的季度营收约是REGENXBIO Inc.的1.2倍（$35.2M vs $30.3M），Byrna Technologies Inc.净利率更高（9.5% vs -221.3%，领先230.9%），REGENXBIO Inc.同比增速更快（43.0% vs 26.0%），Byrna Technologies Inc.自由现金流更多（$8.1M vs $-52.8M），过去两年Byrna Technologies Inc.的营收复合增速更高（45.5% vs 39.4%）
Byrna Technologies Inc.是一家专注于非致命个人安全及自卫产品研发、生产与销售的企业，核心产品包括手持式动能发射器、专用非致命投射弹及相关配件，服务个人消费者、执法机构、私营安保公司及教育机构，核心市场覆盖北美并正拓展全球布局。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BYRN vs RGNX — 直观对比
营收规模更大
BYRN
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出17.0%
26.0%
净利率更高
BYRN
高出230.9%
-221.3%
自由现金流更多
BYRN
多$60.9M
$-52.8M
两年增速更快
BYRN
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $30.3M |
| 净利润 | $3.4M | $-67.1M |
| 毛利率 | 59.8% | — |
| 营业利润率 | 11.2% | -190.0% |
| 净利率 | 9.5% | -221.3% |
| 营收同比 | 26.0% | 43.0% |
| 净利润同比 | -65.2% | -31.2% |
| 每股收益（稀释后） | $0.14 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BYRNRGNX
| Q4 25 | $35.2M | $30.3M | ||
| Q3 25 | $28.2M | $29.7M | ||
| Q2 25 | $28.5M | $21.4M | ||
| Q1 25 | $26.2M | $89.0M | ||
| Q4 24 | $28.0M | $21.2M | ||
| Q3 24 | $20.9M | $24.2M | ||
| Q2 24 | $20.3M | $22.3M | ||
| Q1 24 | $16.7M | $15.6M |
净利润BYRNRGNX
| Q4 25 | $3.4M | $-67.1M | ||
| Q3 25 | $2.2M | $-61.9M | ||
| Q2 25 | $2.4M | $-70.9M | ||
| Q1 25 | $1.7M | $6.1M | ||
| Q4 24 | $9.7M | $-51.2M | ||
| Q3 24 | $1.0M | $-59.6M | ||
| Q2 24 | $2.1M | $-53.0M | ||
| Q1 24 | $17.0K | $-63.3M |
毛利率BYRNRGNX
| Q4 25 | 59.8% | — | ||
| Q3 25 | 60.1% | — | ||
| Q2 25 | 61.6% | — | ||
| Q1 25 | 60.8% | — | ||
| Q4 24 | 62.8% | 70.2% | ||
| Q3 24 | 62.4% | 48.8% | ||
| Q2 24 | 62.0% | 52.5% | ||
| Q1 24 | 57.9% | 72.6% |
营业利润率BYRNRGNX
| Q4 25 | 11.2% | -190.0% | ||
| Q3 25 | 10.2% | -176.3% | ||
| Q2 25 | 11.7% | -296.3% | ||
| Q1 25 | 6.5% | 13.6% | ||
| Q4 24 | 14.6% | -242.1% | ||
| Q3 24 | 4.0% | -256.6% | ||
| Q2 24 | 9.4% | -251.3% | ||
| Q1 24 | -1.0% | -408.8% |
净利率BYRNRGNX
| Q4 25 | 9.5% | -221.3% | ||
| Q3 25 | 7.9% | -208.3% | ||
| Q2 25 | 8.5% | -331.8% | ||
| Q1 25 | 6.3% | 6.8% | ||
| Q4 24 | 34.6% | -241.3% | ||
| Q3 24 | 4.9% | -246.3% | ||
| Q2 24 | 10.2% | -237.7% | ||
| Q1 24 | 0.1% | -405.4% |
每股收益（稀释后）BYRNRGNX
| Q4 25 | $0.14 | $-1.30 | ||
| Q3 25 | $0.09 | $-1.20 | ||
| Q2 25 | $0.10 | $-1.38 | ||
| Q1 25 | $0.07 | $0.12 | ||
| Q4 24 | $0.42 | $-0.99 | ||
| Q3 24 | $0.04 | $-1.17 | ||
| Q2 24 | $0.09 | $-1.05 | ||
| Q1 24 | $0.00 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $65.8M | $102.7M |
| 总资产 | $84.5M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BYRNRGNX
| Q4 25 | $15.5M | $230.1M | ||
| Q3 25 | $9.0M | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | $19.3M | $267.9M | ||
| Q4 24 | $25.7M | $234.7M | ||
| Q3 24 | $20.1M | $255.5M | ||
| Q2 24 | $24.8M | $290.4M | ||
| Q1 24 | $24.2M | $338.7M |
股东权益BYRNRGNX
| Q4 25 | $65.8M | $102.7M | ||
| Q3 25 | $63.1M | $161.5M | ||
| Q2 25 | $60.1M | $213.7M | ||
| Q1 25 | $56.8M | $274.2M | ||
| Q4 24 | $54.4M | $259.7M | ||
| Q3 24 | $44.5M | $301.4M | ||
| Q2 24 | $45.3M | $348.3M | ||
| Q1 24 | $43.2M | $390.7M |
总资产BYRNRGNX
| Q4 25 | $84.5M | $453.0M | ||
| Q3 25 | $78.6M | $525.2M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | $71.0M | $490.9M | ||
| Q4 24 | $71.9M | $466.0M | ||
| Q3 24 | $59.0M | $519.1M | ||
| Q2 24 | $57.5M | $569.4M | ||
| Q1 24 | $52.7M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $8.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 23.1% | -174.0% |
| 资本支出强度资本支出/营收 | 5.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 2.95× | — |
| 过去12个月自由现金流最近4个季度 | $-9.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BYRNRGNX
| Q4 25 | $9.9M | $-52.3M | ||
| Q3 25 | $-2.3M | $-56.0M | ||
| Q2 25 | $-5.5M | $-49.3M | ||
| Q1 25 | $-3.8M | $33.6M | ||
| Q4 24 | $7.3M | $-31.6M | ||
| Q3 24 | $-1.4M | $-40.5M | ||
| Q2 24 | $1.9M | $-45.5M | ||
| Q1 24 | $3.9M | $-55.5M |
自由现金流BYRNRGNX
| Q4 25 | $8.1M | $-52.8M | ||
| Q3 25 | $-4.5M | $-56.5M | ||
| Q2 25 | $-6.4M | $-49.7M | ||
| Q1 25 | $-6.4M | $32.6M | ||
| Q4 24 | $6.3M | $-32.7M | ||
| Q3 24 | $-2.1M | $-40.9M | ||
| Q2 24 | $1.4M | $-46.0M | ||
| Q1 24 | $3.8M | $-56.0M |
自由现金流率BYRNRGNX
| Q4 25 | 23.1% | -174.0% | ||
| Q3 25 | -16.0% | -189.9% | ||
| Q2 25 | -22.4% | -232.8% | ||
| Q1 25 | -24.5% | 36.6% | ||
| Q4 24 | 22.5% | -154.2% | ||
| Q3 24 | -10.0% | -168.9% | ||
| Q2 24 | 7.0% | -206.2% | ||
| Q1 24 | 22.6% | -358.5% |
资本支出强度BYRNRGNX
| Q4 25 | 5.1% | 1.7% | ||
| Q3 25 | 8.0% | 1.7% | ||
| Q2 25 | 3.3% | 1.8% | ||
| Q1 25 | 10.1% | 1.2% | ||
| Q4 24 | 3.4% | 5.1% | ||
| Q3 24 | 3.3% | 1.3% | ||
| Q2 24 | 2.6% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率BYRNRGNX
| Q4 25 | 2.95× | — | ||
| Q3 25 | -1.01× | — | ||
| Q2 25 | -2.25× | — | ||
| Q1 25 | -2.27× | 5.53× | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | -1.36× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 231.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BYRN
| E Commerce | $23.0M | 65% |
| Wholesale Dealerdistributors | $10.9M | 31% |
| Other | $1.3M | 4% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
